Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $58.61 USD
Change Today +1.09 / 1.89%
Volume 4.5M
MRK On Other Exchanges
Symbol
Exchange
New York
Mexico
EN Paris
Sao Paulo
Frankfurt
As of 11:55 AM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).

merck & co. inc. (MRK) Snapshot

Open
$57.69
Previous Close
$57.52
Day High
$58.63
Day Low
$57.64
52 Week High
01/13/15 - $63.62
52 Week Low
10/16/14 - $52.49
Market Cap
165.6B
Average Volume 10 Days
8.5M
EPS TTM
$2.04
Shares Outstanding
2.8B
EX-Date
09/11/15
P/E TM
28.7x
Dividend
$1.80
Dividend Yield
3.07%
Current Stock Chart for MERCK & CO. INC. (MRK)

merck & co. inc. (MRK) Details

Merck & Co., Inc. provides health care solutions worldwide. The company offer therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases. It also offers neuromuscular blocking agents for use in surgery; anti-bacterial products for skin and skin structure infections; antidepressants; ophthalmic and cholesterol modification products; non-sedating antihistamine; and vaginal contraceptive implants. In addition, the company provides products to prevent chemotherapy-induced and post-operative nausea and vomiting; to treat brain tumors and melanoma; to prevent diseases caused by human papillomavirus, as well as vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers animal health products, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics for, and vaccines against bacterial and viral disease in fish. Additionally, the company provides companion animal products, such as diabetes mellitus treatment drugs and vaccines for dogs and cats; ointments for acute and chronic otitis; anthelmintic products; chewable tablets to kill fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. The company serves drug wholesalers and retailers, hospitals, government entities and agencies, physicians, physician distributors, veterinarians, distributors, and animal producers, as well as managed health care providers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey. Merck & Co. Inc formerly operated as a subsidiary of Merck KGaA.

70,000 Employees
Last Reported Date: 02/27/15
Founded in 1891

merck & co. inc. (MRK) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.5M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $3.2M
Executive Vice President and President of Mer...
Total Annual Compensation: $1.5M
President of Global Human Health and Executiv...
Total Annual Compensation: $962.4K
Compensation as of Fiscal Year 2014.

merck & co. inc. (MRK) Key Developments

Merck & Co. Inc. Approves Adopts Amendments to its By-laws

On july 22, 2015, the board of Merck & Co. Inc. approved and adopted amendments to the company’s by-laws (the by-laws). the principal change to the by-laws includes the addition of a new section 3 under article ii, which implements proxy access and allows eligible shareholders who comply with the requirements set forth in the by-laws to include their own nominees for director in the company’s proxy statement along with the candidates nominated by the board. pursuant to the proxy access provision, a shareholder or a group of no more than 20 shareholders, who has maintained continuous qualifying ownership of at least 3% of the company’s outstanding common stock for at least three years and has complied with the other requirements set forth in the by-laws, may include director nominees constituting up to 20% of the board in the company’s proxy materials for an annual meeting of shareholders. the proxy access provision will be first available to shareholders in connection with the company’s 2016 annual meeting of shareholders. additional amendments to the by-laws of the company are as follows: amendment to section 6 of article i to clarify and update the advance notice requirements and procedures for shareholders to present business for consideration by the shareholders at an annual meeting of the shareholders; amendment to section 2 of article ii to clarify and update the advance notice requirements and procedures for shareholders to nominate candidates for election as directors of the company at an annual meeting or a special meeting of shareholders; amendment to article v relating to indemnification by the company of directors and others in connection with any proceeding, investigation or appeal as defined in the by-laws; and other non-substantive changes.

Merck Announces Board Appointments

Merck announced that Pamela J. Craig, retired chief financial officer of Accenture, and Dr. Paul B. Rothman, dean of the medical faculty, vice president for medicine of The Johns Hopkins University and chief executive officer of Johns Hopkins Medicine, will join the company’s board of directors, effective Sept. 1, 2015. The addition expands the Merck board to 14 members. Ms. Craig will serve as a member of the company’s audit committee, and Dr. Rothman will serve as a member of the company’s research committee. They will both stand for election by the company’s shareholders in May 2016. Ms. Craig served as the chief financial officer of Accenture, from 2006 until her retirement in 2013. Dr. Rothman oversees the Johns Hopkins Health System and school of medicine. A rheumatologist and molecular immunologist, he joined Johns Hopkins in July 2012 after having served as dean of the Carver College of Medicine at the University of Iowa and leader of its clinical practice plan since 2008.

Merck & Co. Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Revises Earnings Guidance for the Full Year 2015

Merck & Co. Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported sales of $9,785 million compared to $10,934 million a year ago. Income before taxes was $807 million compared to $1,891 million a year ago. Net income attributable to the company was $687 million or $0.68 per diluted share compared to $2,004 million or $0.30 per diluted share a year ago. On non-GAAP basis, sales were $9,785 million. Income before taxes was $3,298 million. Net income attributable to the company was $2,441 million or $0.86 per diluted share. For the six months, the company reported sales of $19,210 million compared to $21,198 million a year ago. Income before taxes was $2,188 million compared to $3,982 million a year ago. Net income attributable to the company was $1,639 million or $1.25 per diluted share compared to $3,709 million or $0.82 per diluted share a year ago. On non-GAAP basis, sales were $19,210 million. Income before taxes was $6,430 million. Net income attributable to the company was $4,866 million or $1.70 per diluted share. The company has narrowed and raised its full-year 2015 non-GAAP EPS range to be between $3.45 and $3.55, including a negative impact from foreign exchange. The range excludes acquisition- and divestiture-related costs, costs related to restructuring programs and certain other items. The company has lowered its full-year 2015 GAAP EPS range to be between $1.52 and $1.71. The change in the GAAP EPS range reflects the incorporation of foreign exchange losses related to Venezuela, as well as the anticipated gain on the previously announced sale of certain migraine clinical development programs. At current exchange rates, the company now anticipates full-year 2015 revenues to be between $38.6 billion and $39.8 billion, including a negative impact from foreign exchange and approximately $1 billion of net lost sales from acquisitions and divestitures. The company now anticipates its full-year 2015 non-GAAP tax rate will be in the range of 23% to 24%, not including a 2015 R&D tax credit. Net decrease in income before taxes is expected to be in the range of $6,915 million to $6,615 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MRK:US $58.61 USD +1.09

MRK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $151.38 USD +0.27
Amgen Inc $172.13 USD -0.61
Bayer AG €134.95 EUR +3.94
Gilead Sciences Inc $117.02 USD +3.95
GlaxoSmithKline PLC 1,375 GBp +46.00
View Industry Companies
 

Industry Analysis

MRK

Industry Average

Valuation MRK Industry Range
Price/Earnings 14.8x
Price/Sales 3.9x
Price/Book 3.4x
Price/Cash Flow 14.4x
TEV/Sales 2.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MERCK & CO. INC., please visit www.merck.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.